Author(s): Niederkorn JY
Abstract Share this page
Abstract Corneal transplants have been successfully performed in human subjects for over 100 years and enjoy an immune privilege that is unrivaled in the field of transplantation. Immune privilege is defined as the reduced incidence and tempo in the immune rejection of corneal allografts compared to other categories of organ allografts performed under the same conditions. Skin allografts transplanted across various MHC or minor histocompatibility barriers undergo rejection in approximately 100\% of the hosts. By contrast, orthotopic corneal allografts experience long-term survival in 50\% to >90\% of the hosts, depending on the histocompatibility barriers that confront the host. The capacity of corneal allografts to evade immune rejection is attributable to multiple anatomical, physiological and immunoregulatory conditions that conspire to prevent the induction and expression of alloimmunity.
This article was published in Int Rev Immunol
and referenced in Journal of Clinical & Experimental Ophthalmology